IGC
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
India Globalization Capital (IGC) currently holds a Neutral rating within the 40.0 composite band. This reflects moderate conviction given a score of 3 out of 5. The strongest contributions to this composite arise from the regulatory pillar, which surpasses others like fundamentals, market, and editorial at 49.0. The strength in regulatory adherence is offset by challenges in fundamentals and editorial coverage, resulting in an overall cautious stance.
Looking closer at IGC's financials, the company faces difficulties with revenue contraction and negative operating margins, indicating ongoing profitability challenges. Year-over-year revenue growth is down, while gross margins remain relatively solid, suggesting potential pricing discipline. However, operating as well as EBITDA margins remain deep in the negative territory, contributing to a "stretched" financial condition that challenges liquidity. Importantly, these figures demonstrate a mismatch between ongoing expenses and revenue generation. The firm’s market capitalization remains at a lower tier, further emphasizing the financial stretch but suggests potential volatility due to market scale.
Regulatory stability signifies a crucial positive for IGC, particularly as there have been no enforcement actions in recent periods, which reinforces confidence in compliance with US jurisdiction standards. Absent recent regulatory events reflects stability within an otherwise volatile industry. Attention should be directed toward IGC's future operations, particularly around regulatory filings, to help solidify investor sentiment. These filings will serve as critical insights into the firm's compliance posture and enable further evaluation of its positioning in the regulatory landscape. Moreover, consistent adherence to regulatory expectations will potentially provide the necessary buffer to navigate financial challenges and bolster investor confidence.
- IR / PR agency
- IMS Investor Relations
- IR email
- [info@igcpharma.com](mailto:info@igcpharma.com)
- IR page
- Investor relations
- Headquarters
- 10224 FALLS ROAD, POTOMAC, MD, 20854
- Phone
- 301-529-4996
- CEO
- Ram Mukunda
- CFO
- Claudia Grimaldi
- SEC CIK
- 1326205
- Website
- Company website
- Market cap
- $28.4M
- Enterprise value
- $29.1M
- Price to book
- 4.64
- Price to sales
- 25.67
- EV / EBITDA
- 27.31
- Revenue (TTM)
- $1.1M
- Gross profit (TTM)
- $511K
- EBITDA
- $-7.5M
- Operating margin
- -722.7%
- Profit margin
- 0.0%
- Rev growth YoY
- -3.9%
- Return on equity
- -83.3%
- Return on assets
- -50.3%
- EPS (TTM)
- $-0.06
- EPS est. current year
- $-0.08
- Wall St. target price
- $4.25
- Shares outstanding
- 104.4M
- Insider ownership
- 13.4%
- Institutional ownership
- 21.7%
- Beta
- 0.46
- Full-time employees
- 70
- GICS sector
- Healthcare
- GICS industry
- Biotechnology
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for IGC (IGC)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for IGC (IGC), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for IGC are maintained by Cannabis Investor News and refreshed throughout the trading day.